
RISA’s raison d’être (reason of existence): Making Institutions Win, starting in oncology. Our Mission: Starting in Oncology, we design AI Operating System that helps leading institutions win by configuring BOSS Console around their real-world workflows.

RISA’s raison d’être (reason of existence): Making Institutions Win, starting in oncology. Our Mission: Starting in Oncology, we design AI Operating System that helps leading institutions win by configuring BOSS Console around their real-world workflows.
Focus: Oncology-first AI operating system (BOSS) for clinical and operational workflow automation
Key use cases: Prior authorization, eligibility/benefit verification, claims tracking, denial management
Recent funding: $11.1M Series A (Jan 13, 2026) after a $3.5M seed (Apr 17, 2025)
Headcount: ~104 employees
Operational inefficiencies and treatment delays in oncology due to fragmented systems, complex payer policies, and manual workflows.
Healthtech / AI
$3.5M
$11.1M
Participation from Oncology Ventures, Z21 Ventures, and John Simon (Ventureforgood)
| Company |
|---|